UBS Group’s Taiwan Liposome Company, Ltd. American Depository Shares TLC Stock Holding History

UBS Group’s Portfolio TLC Stock Details TLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,165	Closed	-$7K	–	10649
2021 Q2	$7K	Buy	+1,165	New	+$6.68K	﹤0.01%	8408
2020 Q3	–	Sell	-1,014	Closed	-$6K	–	8658
2020 Q2	$6K	Buy	+1,014	New	+$4.9K	﹤0.01%	7337
2020 Q1	–	Sell	-736	Closed	-$4K	–	8640
2019 Q4	$4K	Sell	736 -954	-56%	-$4.95K	﹤0.01%	7704
2019 Q3	$9K	Buy	1,690 +408	+32%	+$2.11K	﹤0.01%	7243
2019 Q2	$7K	Buy	1,282 +1,245	+3,365%	+$6.96K	﹤0.01%	7277
2019 Q1	$0	Sell	37 -3,311	-99%	-$20.4K	﹤0.01%	8387
2018 Q4	$18K	Buy	+3,348	New	+$19.9K	﹤0.01%	6890

UBS Group's TLC Position: Q3 2021 in Review

UBS Group sold out of Taiwan Liposome Company, Ltd. American Depository Shares (TLC) in Q3 2021, closing a stake of 1,165 shares — an estimated $7K sold.

UBS Group first reported a position in TLC in Q4 2018 and held it in 7 quarters. The position peaked at $18K in Q4 2018. 0 funds tracked by Wall St. Rank hold TLC as of Q3 2021.

UBS Group reported no remaining Taiwan Liposome Company, Ltd. American Depository Shares position as of Q3 2021 after selling out during the quarter.
UBS Group sold 1,165 Taiwan Liposome Company, Ltd. American Depository Shares shares in Q3 2021, an estimated $7K.
UBS Group first reported a position in Taiwan Liposome Company, Ltd. American Depository Shares in Q4 2018 and held it in 7 quarters.
UBS Group's Taiwan Liposome Company, Ltd. American Depository Shares position peaked at $18K in Q4 2018.
0 funds tracked by Wall St. Rank held Taiwan Liposome Company, Ltd. American Depository Shares as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.